Mega Genomics

Mega Genomics Inventory

The Inventory of Mega Genomics (6667.HK) as of Nov 19, 2026 is 46.07 M CNY. In the previous year, Inventory was 5.38 M CNY — a change of 756.95% (higher).

Inventory

46.07 MCNY

YoY

756.95%

Last updated:

Inventory of Mega Genomics is 2025 46.07 M CNY. Inventory of Mega Genomics was 2024 5.38 M CNY. It decreases by 756.95% higher compared to the previous year.

The Mega Genomics Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2019
2.44 M CNY
Jan 1, 2020
2.97 M CNY
Jan 1, 2021
3.83 M CNY
Jan 1, 2022
4.09 M CNY
Jan 1, 2023
4.41 M CNY
Jan 1, 2024
5.38 M CNY
Jan 1, 2025
46.07 M CNY
The Mega Genomics Inventory history
YEARInventoryYoY
46.07 MCNY+756.95%
5.38 MCNY+21.94%
4.41 MCNY+7.74%
4.09 MCNY+6.82%
3.83 MCNY+28.90%
2.97 MCNY+21.80%
2.44 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mega Genomics Stock analysis

What does Mega Genomics do? Mega Genomics Ltd. generates revenue through three business segments. The Consumer Genetic Testing Services segment offers nutrition and metabolism testing, cancer risk assessment, chronic disease susceptibility analysis, pharmacogenetic testing, and infectious disease testing to individual consumers. The Cancer Screening Services segment provides specific tests including Septin9 for colorectal cancer, Syndecan-2 (SDC2) for colorectal cancer, and ring finger protein 180 (RNF180)/Septin9 for gastric cancer screening. The Other Services segment delivers genetic research and analysis services to third-party research institutions, creating additional revenue streams from institutional partnerships. The primary buyers for Consumer Genetic Testing Services are individual consumers seeking personalized health insights. Cancer Screening Services are utilized by healthcare providers and patients for early detection of colorectal and gastric cancers. Third-party research institutions purchase genetic research and analysis services from the Other Services segment to support their scientific studies and development projects. Mega Genomics Ltd. serves distinct market segments: individual consumers for genetic testing, healthcare providers for cancer screening, and research institutions for specialized genetic analysis. The company's revenue model relies on direct consumer sales, healthcare provider contracts, and institutional research partnerships to sustain its operations and growth. Mega Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mega Genomics stock

Inventory of Mega Genomics is 46.07 M CNY in 2025.

Inventory of Mega Genomics changed from 5.38 M CNY to 46.07 M CNY, representing a 756.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Mega Genomics since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Mega Genomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Mega Genomics

All Key Metrics — Mega Genomics